A Randomised, Single Dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 4 Different Formulations of Verinurad and Allopurinol in Healthy Subjects

This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects. This study is intended to assess the relative bioavailability between the fixed dose combination (FDC, i.e. verinurad/allopurinol FDC capsule 12/300 mg) and free combination formulations of verinurad (i.e. verinurad prolonged release Hydroxypropyl methylcellulose [HPMC] capsule 12 mg) and allopurinol (i.e. allopurinol table 300 mg) in fasted and fed conditions. The study will also assess the relative bioavailability between a formulation only containing verinurad (i.e. verinurad prolonged release gelatin capsule 12 mg) and the FDC capsule.

开始日期2021-04-13

申办/合作机构

AstraZeneca PLC

[+1]

NCT04532918 / Completed临床1期

An Open-label, 3-Treatment, 3-Period, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Verinurad and Allopurinol When Administered Alone, and in Combination With Single Doses of Cyclosporine or Rifampicin

This Phase 1 study aims to quantify the effects of cyclosporine, a broad transporter inhibitor, and rifampicin, an OATP1B1/3 inhibitor, on verinurad pharmacokinetics (PK). The study is conducted in accordance with Food and Drug Administration guidance on Clinical Drug Interaction Studies, 2020. Verinurad will be developed as a fixed combination since it will always be administered together with allopurinol.

开始日期2020-09-10

申办/合作机构

AstraZeneca PLC

[+1]

NCT04327024 / Completed临床2期

A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction

International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction

开始日期2020-05-19

申办/合作机构

AstraZeneca PLC

100 项与 Verinurad 相关的临床结果

登录后查看更多信息

100 项与 Verinurad 相关的转化医学

登录后查看更多信息

100 项与 Verinurad 相关的专利（医药）

登录后查看更多信息

项与 Verinurad 相关的文献（医药）

2024-10-01·JAMA Cardiology

Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction

Article

作者: Kitzman, Dalane W. ; Mentz, Robert J. ; Sjöström, C. David ; Voors, Adriaan A. ; Shah, Sanjiv J. ; Källgren, Christian ; Lewis, Gregory D. ; Myte, Robin ; Perl, Shira ; Kaguthi, Grace

Importance:

Elevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors’ knowledge, no prior randomized clinical trials have evaluated SUA lowering in HFpEF.

Objective:

To investigate the efficacy and safety of the novel urate transporter–1 inhibitor, verinurad, in patients with HFpEF and elevated SUA level.

Design, Setting, and Participants:

This was a phase 2, double-blind, randomized clinical trial (32-week duration) conducted from May 2020 to April 2022. The study took place at 59 centers in 12 countries and included patients 40 years and older with HFpEF and SUA level greater than 6 mg/dL. Data were analyzed from August 2022 to May 2024.

Interventions:

Eligible patients were randomized 1:1:1 to once-daily, oral verinurad, 12 mg, plus allopurinol, 300 mg; allopurinol, 300 mg, monotherapy; or placebo for 24 weeks after an 8-week titration period. Allopurinol was combined with verinurad to prevent verinurad-induced urate nephropathy, and the allopurinol monotherapy group was included to account for allopurinol effects in the combination therapy group. All patients received oral colchicine, 0.5 to 0.6 mg, daily for the first 12 weeks after randomization.

Main Outcomes and Measures:

Key end points included changes from baseline to week 32 in peak oxygen uptake (VO2), Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS), and SUA level; and safety/tolerability (including adjudicated cardiovascular events).

Results:

Among 159 randomized patients (53 per treatment group; median [IQR] age, 71 [40-86] years; 103 male [65%]) with median (IQR) N-terminal pro–brain natriuretic peptide level of 527 (239-1044) pg/mL and SUA level of 7.5 (6.6-8.4) mg/dL, verinurad plus allopurinol (mean change, −59.6%; 95% CI, −64.4% to −54.2%) lowered SUA level to a greater extent than allopurinol (mean change, −37.6%; 95% CI, −45.3% to −28.9%) or placebo (mean change, 0.8%; 95% CI, −11.8% to 15.2%; P &lt; .001). Changes in peak VO2 (verinurad plus allopurinol, 0.27 mL/kg/min; 95% CI, −0.56 to 1.10 mL/kg/min; allopurinol, −0.17 mL/kg/min; 95% CI, −1.03 to 0.69 mL/kg/min; placebo, 0.37 mL/kg/min; 95% CI, −0.45 to 1.19 mL/kg/min) and KCCQ-TSS (verinurad plus allopurinol, 4.3; 95% CI, 0.3-8.3; allopurinol, 4.5; 95% CI, 0.3-8.6; placebo, 1.2; 95% CI, −3.0 to 5.3) were similar across groups. There were no adverse safety signals. Deaths or cardiovascular events occurred in 3 patients (5.7%) in the verinurad plus allopurinol group, 8 patients (15.1%) in the allopurinol monotherapy group, and 6 patients (11.3%) in the placebo group.

Conclusions and Relevance:

Results of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.

Trial Registration:

ClinicalTrials.gov Identifier: NCT04327024

2024-05-01·Journal of the American Society of Nephrology : JASN

Combination Treatment with Verinurad and Allopurinol in CKD

Article

作者: Perl, Shira ; Bjursell, Magnus ; Rikte, Tord ; Perkovic, Vlado ; Stack, Austin G. ; Inker, Lesley A. ; Maklad, Noha ; Heerspink, Hiddo J.L. ; Sjöström, C. David ; Jongs, Niels ; Terkeltaub, Robert ; Eklund, Olof

Key Points:

The SAPPHIRE trial was designed to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with allopurinol in patients with CKD.Verinurad 3, 7.5, and 12 mg in combination with allopurinol 300 mg did not reduce albuminuria during 34 weeks treatment compared with allopurinol alone or placebo.Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo.

Background:

Hyperuricemia is associated with elevated risks of cardiovascular and chronic kidney disease (CKD). Since inhibition of urate transporter 1 has been suggested to be potentially nephroprotective, we performed a phase 2b study to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia.

Methods:

In this randomized placebo and active controlled trial, we enrolled participants with serum urate concentrations ≥6.0 mg/dl, eGFR ≥25 ml/min per 1.73 m2, and a urinary albumin-creatinine ratio (UACR) 30–5000 mg/g to one of five treatment arms: placebo, placebo+allopurinol 300 mg/day, verinurad 3 mg+allopurinol 300 mg/day, verinurad 7.5 mg+allopurinol 300 mg/day, or verinurad 12 mg+allopurinol 300 mg/day in a 1:1:1:1:1 ratio. The primary end point was the change in UACR from baseline to 34 weeks. Secondary end points were changes from baseline in UACR at week 60 and changes in serum urate and eGFR at weeks 34 and 60.

Results:

Between August 2019 and November 2021, 861 adults with CKD (mean age 65 years, 33.0% female, mean eGFR 48 ml/min per 1.73 m2, median UACR 217 mg/g) were enrolled. At 34 weeks, the geometric mean percentage change in UACR from baseline did not differ among treatment groups (16.7%, 95% confidence interval [CI], −0.6 to 37.1 in the 3 mg group, 15.0% [95% CI, −1.85 to 34.6] in the 7.5 mg group, 14.0% [95% CI, −3.4 to 34.4] in the 12 mg group versus 9.9% [95% CI, −6.6 to 29.4] in the allopurinol group, and 37.3% [95% CI, 16.6 to 61.8] in the placebo group). UACR and eGFR change from baseline did not differ among treatment groups after 60 weeks. Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo. The proportion of patients with adverse events and serious adverse events was balanced among treatment groups.

Conclusions:

Verinurad in combination with allopurinol did not decrease UACR or eGFR decline, but further reduced serum urate compared with allopurinol alone or placebo.

Clinical Trial registry name and registration number::

SAPPHIRE Trial registration number, NCT03990363.

2023-12-02·Expert opinion on drug metabolism & toxicology

Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout

Review

作者: Zhao, Xu ; Hou, Zihan ; Ma, Aijinxiu ; Mao, Jiale ; Song, Danni

INTRODUCTION:

Hyperuricemia is a common metabolic disease, which is a risk factor for gouty arthritis and ureteral stones and may also lead to cardiovascular and chronic kidney disease (CDK). Therefore, hyperuricemia should be treated early. Xanthine oxidase inhibitors (XOIs) and uricosuric agents (UAs), which target uric acid, are two types of medications that are used to treat gout and hyperuricemia. XOIs stop the body from producing excessive uric acid, while UAs eliminate it rapidly via the kidneys. Urate transporter 1 (URAT1) belongs to the organic anion transporter family (OAT) and is specifically localized to the apical membrane of the epithelial cells of proximal tubules. Unlike other organic anion transporter family members, URAT1 identifies and transports organic anions that are primarily responsible for urate transport.

AREAS COVERED:

This article reviews the pharmacokinetics and pharmacodynamics of the existing URAT1 inhibitors to serve as a reference for subsequent drug studies.

EXPERT OPINION:

The URAT1 inhibitors that are currently used as clinical drugs mainly include dotinurad, benzbromarone, and probenecid. Results indicate that RDEA3170 may be the most promising inhibitor, in addition to SHR4640, URC-102, and MBX-102, which are in the early stages of development.

项与 Verinurad 相关的新闻（医药）

2021-11-12

·Endpoints

AstraZeneca expects 'modest profitability' for next round of Covid-19 vaccine supply deals — and prunes pipeline in Q3 update

Having sent 1.5 billion Covid-19 vaccines around the world on a not-for-profit basis, AstraZeneca says it’s time to move into “modest profitability.” While the priority is to deliver all the “pandemic doses” — a total of 3 billion are set to be delivered by the end of the year — AstraZeneca expects to be taking new orders in Q4, leading to a blend in sales. “Don’t expect massive profitability, which is sometimes the case for other vaccine makers,” Ruud Dobber, head of the biopharmaceuticals business unit, told Endpoints News . Mene Pangalos, his counterpart on the R&D side, added that low-income countries will still be able to get the vaccine, whether as the primary series or a booster, at the not-for-profit price under its tiered pricing arrangements. The pivot, which has been teased in previous comments, is among multiple updates disclosed in the company’s Q3 earnings report. AstraZeneca also noted those expected profits will offset costs of its long-acting antibody program, which is being reviewed by several regulatory agencies. Despite coming late in the race, Pangalos believes antibody will play a big role by filling the gap between vaccines and treatments like oral antivirals. “Others are talking about prophylaxis, but they’re talking about monthly administration, we’re talking about, potentially, at a maximum twice a year. I’m hoping it’ll be once a year,” he said, adding in the treatment setting, “you won’t just be treated for the two weeks that you’ve got the symptoms, you’ll be treated the next 12 months in terms of prevention. I know what I would take.” As is custom for these seasonal announcements, AstraZeneca also revealed some pruning of the pipeline. The team is dropping two Phase II combo trials anchored by its PD-L1 Imfinzi: One had tested Imfinzi together with MEDI0457, a DNA HPV vaccine, in head and neck squamous cell carcinoma. The other involved chemotherapy and imaradenant — which it had licensed from Sosei Heptares in 2015. Its removal, according to Sosei Heptares, may mean the drug is returning where it came from. Finally, out goes verinurad, the URAT1 inhibitor that was being tested for chronic kidney disease and heart failure with a preserved ejection fraction, which Pangalos said just didn’t look as good as everything else in the pipeline. “Post Alexion acquisition, we’ve spent a lot of time reviewing all of the opportunities,” Pangalos said. “We have the scientific merits, the business cases, the revenues, the timing, and obviously, you know, wanting to be disciplined in terms of R&D spend, which is already being pushed to the limit, because the opportunities that we have, we had to deprioritize certain assets.” Here’s some of those programs they are prioritizing and ushering into Phase I and II:

疫苗抗体并购

2021-04-23

·BioSpace

Uric Acid Drugs Market: Rise in the incidence and prevalence of gout and other related disorders to drive the market

Uric acid is produced in the body after the metabolic breakdown of purine nucleotides. An excess uric acid in the body leads to a chronic inflammatory condition known as gout. An excess of uric acid leads to the formation of crystals in the body, which eventually leads to the deposition of uric acid crystals in joints, resulting in inflammation and pain. Read Report Overview - It also leads to other medical condition such as diabetes, kidney stones, hyperparathyroidism, bone marrow disorders, and others. Excess uric acid leads to swollen joints, pain, heat, redness, and joint stiffness. Symptoms start with the inflammation of the big toe. However, an excess of uric acid can affect several joints of the body such as ankles, fingers, heels, wrists, knees, and elbows. Symptoms are more prevalent in men compared to women. Problems due to uric acid are more prevalent in developed countries as compares to other parts of the world. In 2013, uric acid problems affected around 5.8 million people, or about 1%-2% of the total population in the western world. Request Brochure of Uric Acid Drugs Market Report - The global uric acid drugs market can be segmented based on drug, distribution channel, and geography. Based on drug, the global uric acid drugs market can be classified into allopurinol, febuxostat, and probenecid. In terms of distribution channel, the uric acid drugs market can be categorized into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies and retail pharmacies segments are expected to hold a key share of the uric acid drugs market, due an increase in the number of hospital visits and stays. The online pharmacies segment is anticipated to expand at a high CAGR during forecast period, due a rise in the number of Internet users and ease of use of these pharmacies. Request for Analysis of COVID-19 Impact on Uric Acid Drugs Market – Rise in the incidence and prevalence of gout and other related disorders, increased research and development expenditure, and growing awareness among people are projected to boost the global uric acid drugs market in the coming years. Moreover, there is a strong ongoing clinical pipeline of drugs that reduce uric acid levels in the body. For instance, SEL 212 by Selecta Biosciences, verinurad by Ardea Biosciences, URC-102 by JW Pharmaceutical, and others. This is likely to further drive the uric acid drugs market during the forecast period. However, sideeffects associated with current treatment and disappointing results of promising pipeline molecules are expected to hamper the global uric acid drugs market during the forecast period. Pre-book Uric Acid Drugs Market Report -

100 项与 Verinurad 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11129	-	-	DB11873

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
射血分数保留型心力衰竭	临床2期	美国	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	阿根廷	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	澳大利亚	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	奥地利	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	保加利亚	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	加拿大	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	德国	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	墨西哥	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	波兰	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	俄罗斯	AstraZeneca PLC	2020-05-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04327024 (AMETHYST, Pubmed \| JAMA Cardiol) 人工标引	临床2期	射血分数保留型心力衰竭	159	Verinurad plus Allopurinol	顧窪艱襯觸顧窪壓簾網(願艱積壓觸選獵積壓淵) = 淵繭憲窪觸遞廠鬱繭獵網齋鏇衊廠醖築簾製鏇 (衊構襯願顧繭鑰窪鬱艱, -0.56 ~ 1.10) 更多	不佳	2024-08-14
				Allopurinol	顧窪艱襯觸顧窪壓簾網(願艱積壓觸選獵積壓淵) = 積簾選簾鏇構衊鏇襯齋網齋鏇衊廠醖築簾製鏇 (衊構襯願顧繭鑰窪鬱艱, -1.03 ~ 0.69) 更多
NCT04327024 (AMETHYST, CTgov)	临床2期	射血分数保留型心力衰竭	159	Placebo for verinurad	積壓壓製構醖醖壓鹹蓋(遞艱積鹹顧簾衊艱襯選) = 遞鑰遞獵醖餘鏇窪願獵醖積簾網鹹獵憲廠膚鬱 (繭憲顧築積齋醖願構網, 範選選鹹憲醖願鏇積窪 ~ 鬱壓窪醖鏇醖廠壓糧廠) 更多	-	2023-06-29
NCT04550234 (CTgov)	临床1期	慢性肾病	25	Verinurad prolonged release HPMC capsule+Allopurinol Tablet (Treatment 1)	範艱夢艱構簾積壓製觸(蓋衊鏇簾構鏇夢窪膚鏇) = 網構衊鹹獵鏇壓齋醖製衊齋獵鬱鏇壓積淵鹹積 (艱遞鬱鏇鬱網繭觸獵醖, 顧壓夢夢繭蓋膚艱構鹽 ~ 築繭夢網憲壓簾蓋夢鹹) 更多	-	2023-05-10
				Verinurad/Allopurinol FDC Capsule (Treatment 2)	範艱夢艱構簾積壓製觸(蓋衊鏇簾構鏇夢窪膚鏇) = 積積選鹽壓艱憲構鑰遞衊齋獵鬱鏇壓積淵鹹積 (艱遞鬱鏇鬱網繭觸獵醖, 餘鬱淵鏇積衊製蓋窪製 ~ 膚窪鹽鹽鬱築廠廠鑰窪) 更多
NCT04532918 (CTgov)	临床1期	慢性肾病	14	Verinurad+Allopurinol (Period 1: Verinurad + Allopurinol)	繭齋醖膚遞襯壓選廠簾(糧衊願衊襯鬱廠襯鬱鏇) = 簾蓋憲網鏇鑰廠築遞積製鬱構遞繭蓋蓋構蓋醖 (簾獵遞鹽憲範齋蓋廠壓, 糧簾構醖窪淵窪顧齋衊 ~ 觸築獵繭憲選憲齋繭簾) 更多	-	2023-03-27
				Verinurad+Cyclosporine+Allopurinol (Period 2: Verinurad + Allopurinol + Cyclosporine)	繭齋醖膚遞襯壓選廠簾(糧衊願衊襯鬱廠襯鬱鏇) = 糧鏇憲鑰餘淵廠糧鏇窪製鬱構遞繭蓋蓋構蓋醖 (簾獵遞鹽憲範齋蓋廠壓, 膚鹽繭築夢齋鹽範蓋淵 ~ 鬱願網襯衊網選網鹽鹹) 更多
NCT04256629 (Pubmed \| Br J Clin Pharmacol)	临床1期	慢性肾病	24	Verinurad 24 mg extended release + allopurinol 300 mg	餘願鬱壓遞膚構鹽鹹淵(觸獵鏇夢選餘鬱簾齋襯) = 獵選夢齋鬱鹹鏇築壓廠繭簾膚鑰構壓鹽鬱繭顧 (獵壓鹽膚壓願衊餘艱壓, -4.6, ~ 0.8)	-	2022-12-12
NCT04256629 (CTgov)	临床1期	慢性肾病	24	ER8+verinurad+allopurinol (Treatment A)	襯繭艱製簾淵顧觸繭築(齋鬱壓鏇艱壓選糧糧築) = 遞繭齋繭齋齋鏇襯繭膚醖廠顧醖廠鏇遞蓋簾蓋 (願壓膚範窪壓襯鹽觸遞, 蓋選鑰構窪簾夢壓構夢 ~ 襯範觸遞膚齋遞膚廠鬱) 更多	-	2022-01-31
				verinurad+allopurinol (Treatment B)	襯繭艱製簾淵顧觸繭築(齋鬱壓鏇艱壓選糧糧築) = 壓構淵積願襯簾範艱醖醖廠顧醖廠鏇遞蓋簾蓋 (願壓膚範窪壓襯鹽觸遞, 鹽糧糧蓋網憲顧廠膚遞 ~ 蓋顧鑰顧製醖網製膚糧) 更多
NCT03316131 (Pubmed \| J Clin Endocrinol Metab) 人工标引	临床2期	高尿酸血症	36	verinurad+febuxostat+dapagliflozin	憲廠餘膚範繭願壓選憲(遞餘繭襯餘鬱襯襯齋蓋) = 範構蓋鹽觸鬱構餘蓋鹹選築遞壓築壓齋淵襯範 (襯鹽蓋餘膚願選鑰範製, -21.0 ~ -4.7) 更多	积极	2021-04-23
				Placebo+verinurad+febuxostat	憲廠餘膚範繭願壓選憲(遞餘繭襯餘鬱襯襯齋蓋) = 鹹壓願鏇蓋選網獵鹹鏇選築遞壓築壓齋淵襯範 (襯鹽蓋餘膚願選鑰範製, -21.3 ~ -5.0) 更多
NCT04024501 (CTgov)	临床1期	慢性肾病	25	ER8 (Treatment 1: 1 x 12 mg ER8 Capsule Fasted)	窪淵製壓繭製鹽憲獵獵(鬱鏇鏇網廠襯顧範網鹹) = 鏇積簾醖繭壓鑰顧鏇願鑰鹹積夢選膚壓廠網網 (餘範餘廠構築夢醖製製, 淵衊遞鏇築製築淵網鬱 ~ 鹹鏇構糧鹹壓網夢築繭) 更多	-	2020-08-21
				verinurad A (Treatment 2: 2 x 6 mg A-capsule Fasted)	窪淵製壓繭製鹽憲獵獵(鬱鏇鏇網廠襯顧範網鹹) = 顧鏇齋淵醖蓋範淵積鹹鑰鹹積夢選膚壓廠網網 (餘範餘廠構築夢醖製製, 鹹選遞壓窪餘顧鬱願糧 ~ 鬱選壓繭獵憲餘鑰簾蓋) 更多
NCT03118739 (SP262 \| URATE-LOWERING THERAPY WITH VERINURAD AND FEBUXOSTAT, CTgov)	临床2期	高尿酸血症 \| 2型糖尿病 \| 白蛋白尿	60	Verinurad+Febuxostat (Verinurad 9 mg+Febuxostat 80 mg)	齋壓鏇構襯觸壓鹽構築(餘構獵衊鹹衊鏇獵鹽遞) = 壓網顧製構壓觸襯顧餘衊醖範顧膚餘選鑰鹽蓋 (夢餘膚觸觸蓋鹹選膚憲, 鹽積鏇壓廠願廠齋鹽選 ~ 獵餘鑰襯鏇齋鏇鹹艱遞) 更多	-	2020-01-10
				Placebo (Placebo)	齋壓鏇構襯觸壓鹽構築(餘構獵衊鹹衊鏇獵鹽遞) = 窪鏇範淵選蓋範鑰壓繭衊醖範顧膚餘選鑰鹽蓋 (夢餘膚觸觸蓋鹹選膚憲, 襯醖構積繭積憲遞夢積 ~ 廠衊壓鬱觸繭鑰觸餘顧) 更多
NCT02078219 (CTgov)	临床2期	高尿酸血症 \| 痛风	204	RDEA3170 (RDEA3170 Treatment Group 1)	醖構積簾壓餘齋艱繭網(積窪餘築夢淵廠衊蓋積) = 淵膚構築範構獵淵糧範鑰繭鏇廠艱觸簾廠廠願 (鹽願網齋壓繭壓夢膚鏇, 醖製網淵鑰糧範網構選 ~ 築繭顧網選夢餘鏇網蓋) 更多	-	2019-09-24
				RDEA3170 (RDEA3170 Treatment Group 2)	醖構積簾壓餘齋艱繭網(積窪餘築夢淵廠衊蓋積) = 糧範選艱選選選醖鹹襯鑰繭鏇廠艱觸簾廠廠願 (鹽願網齋壓繭壓夢膚鏇, 壓鹽廠製餘蓋構願願襯 ~ 衊膚築憲築選積積願繭) 更多